Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Medicine
FDA Approves Two Enhertu Indications in HER2-Positive Early Breast Cancer
The FDA approved fam-trastuzumab deruxtecan-nxki for two HER2-positive early-stage breast cancer settings, covering neoadjuvant use and adjuvant treatment after residual disease.
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
The FDA approved fam-trastuzumab deruxtecan-nxki, known as T-DXd or Enhertu, for two separate HER2-positive early-stage breast cancer indications on 15 May.
One indication covers neoadjuvant treatment before surgery with T-DXd followed by taxane, trastuzumab and pertuzumab. The second covers adjuvant treatment for patients with residual invasive disease after neoadjuvant trastuzumab-based treatment.
Both indications require HER2-positive disease as determined by an FDA-authorized test, underscoring the diagnostic link built into modern oncology approvals.
Sourcing note: Indication details and biomarker language are from FDA. This article does not compare clinical regimens.
Why It Matters
Antibody-drug conjugates are moving earlier in cancer treatment. The approval expands T-DXd beyond metastatic settings into treatment sequences around surgery.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDAEnhertuHER2Breast CancerOncology